Schizophrenia Market Size, Latest Trends, Growth Status, Top Major Players And Forecast To 2033

The new report published by The Business Research Company, titled Schizophrenia Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the schizophrenia market size has grown strongly in recent years. It will grow from $5.48 billion in 2023 to $5.82 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The schizophrenia market size is expected to see strong growth in the next few years. It will grow to $7.11 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12869&type=smp

Rising Mental Illness Burden Fuels Growth In The Schizophrenia Market
The increasing burden of mental illness is expected to propel the growth of the schizophrenia market going forward. Mental illness refers to a wide range of mental health conditions that affect a person's thinking, feelings, mood and behavior, profoundly impact day-to-day living and may also affect a person's ability to relate to others. The rise in mental illness cases has led to an increase in advancements in schizophrenia treatment and the development of new drugs, driving the growth of the market. For instance, in March 2023, according to the National Institute of Mental Health (NIMH), a US-based Department of Health and Human Services, there were an estimated 57.8 million people aged 18 and older with any mental illness (AMI), representing 22.8% of all adults in the United States. Young adults aged 18-25 years had the highest prevalence of AMI (33.7%), followed by people aged 26-49 years (28.1%) and those aged 50 and beyond (15.0%). Therefore, the increasing burden of mental illness will drive the schizophrenia market.

Adoption Of Automated Psychological Therapy, Including Vr-Based Solutions, By Leading Companies In The Schizophrenia Market
Major companies operating in the schizophrenia market are adopting new technologies, such as automated psychological therapy, to strengthen their position in the market. Automated psychological therapy refers to using technology, such as virtual reality (VR), to provide psychological therapy in an automatic or self-guided manner. For instance, in April 2022, OxfordVR Limited, a Switzerland-based digital therapeutic company, launched gameChangeVR technology, a 6-week automated VR treatment that delivers cognitive behavioral therapy (CBT) within secure, immersive virtual settings. VR-based automated psychological therapy for individuals with mental illnesses Users are coached by a virtual coach rather than a real-life therapist, allowing the treatment to reach many more patients. It is the first time that digital therapy of any type has been proven to treat people with schizophrenia and mood disorders who have psychotic symptoms.

The schizophrenia market covered in this report is segmented -

1) By Type: Catatonic Schizophrenia; Paranoid Schizophrenia; Undifferentiated Schizophrenia; Hebephrenic Schizophrenia; Residual Schizophrenia; Other Types
2) By Treatment: First-Generation Antipsychotics; Second-Generation Antipsychotics; Third-Generation Antipsychotics; Psychotherapies; Other Treatments
3) By Route of Administration: Oral; Injectables

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12869&type=discount

Major players in the schizophrenia market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Otsuka Holdings Co. Ltd., Biogen Inc., Daiichi Sankyo Co. Ltd., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Recordati SpA, Lundbeck A/S, Neurocrine Biosciences Inc., Torrent Pharmaceutical Ltd., Alkermes PLC, Indivior PLC, Vanda Pharmaceuticals Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., PsychoGenics Inc., Karuna Therapeutics Inc., Minerva Neurosciences Inc. .

Contents of the report:
1. Executive Summary
2. Schizophrenia Market Report Structure
3. Schizophrenia Market Trends And Strategies
4. Schizophrenia Market - Macro Economic Scenario
5. Schizophrenia Market Size And Growth
…..
27. Schizophrenia Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/schizophrenia-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.